Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;31(4):e2185.
doi: 10.1002/rmv.2185. Epub 2020 Oct 22.

Alternative clinical specimens for the detection of SARS-CoV-2: A rapid review

Laura Comber  1 , Kieran A Walsh  1 , Karen Jordan  1 , Kirsty K O'Brien  1 , Barbara Clyne  1   2 , Conor Teljeur  1 , Linda Drummond  1 , Paul G Carty  1 , Cillian F De Gascun  3 , Susan M Smith  2 , Patricia Harrington  1 , Máirín Ryan  1   4 , Michelle O'Neill  1
Affiliations
Review

Alternative clinical specimens for the detection of SARS-CoV-2: A rapid review

Laura Comber et al. Rev Med Virol. 2021 Jul.

Abstract

The collection of nasopharyngeal swabs to test for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an invasive technique with implications for patients and clinicians. Alternative clinical specimens from the upper respiratory tract may offer benefits in terms of collection, comfort and infection risk. The objective of this review was to synthesise the evidence for detection of SARS-CoV-2 ribonucleic acid (RNA) using reverse transcription polymerase chain reaction (RT-PCR) tested saliva or nasal specimens compared with RT-PCR tested nasopharyngeal specimens. Searches were conducted in PubMed, Embase, Europe PMC and NHS evidence from December 2019 to 20 July 2020. Eighteen studies were identified; 12 for saliva, four for nasal and two included both specimen types. For saliva-based studies, the proportion of saliva samples testing positive relative to all positive samples in each study ranged from 82.9% to 100%; detection in nasopharyngeal specimens ranged from 76.7% to 100%; positive agreement between specimens for overall detection ranged from 65.4% to 100%. For nasal-based studies, the proportion of nasal swabs testing positive relative to all positive samples in each study ranged from 81.9% to 100%; detection in nasopharyngeal specimens ranged from 70% to 100%; positive agreement between specimens for overall detection ranged from 62.3% to 100%. The results indicate an inconsistency in the detection of SARS-CoV-2 RNA in the specimen types included, often with neither the index nor the reference of interest detecting all known cases. Depending on the test environment, these clinical specimens may offer a viable alternative to standard. However, at present the evidence is limited, of variable quality, and relatively inconsistent.

Keywords: SARS-CoV-2; coronavirus; covid-19; diagnostics; nasal; nasopharyngeal; review; saliva.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens for Covid-19; 2020.
    1. World Health Organisation. Laboratory testing strategy recommendations for Covid-19: interim guidance; 2020.
    1. Cheng MP , Papenburg J , Desjardins M , et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus-2: a narrative review. Ann Intern Med. 2020;172(11):726-734.
    1. Marcotte LM , Liao JM . Incorporating test characteristics into SARS-CoV-2 testing policy-sense and sensitivity. JAMA Health Forum. 2020;1(4):e200448-e200448.
    1. National University of Singapore School of Public Health. Covid-19 science report: diagnostics; 2020.

MeSH terms